Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cutaneous necrotic ulceration due to BCG re-vaccination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  3. What you always needed to know about electroporation based DNA vaccines

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human papillomavirus vaccination in immigrants and descendants of immigrants in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Karl-Ulrich Petry
  • Kaatje Bollaerts
  • Paolo Bonanni
  • Margaret Stanley
  • Rosybel Drury
  • Elmar Joura
  • Susanne K Kjaer
  • Chris J L M Meijer
  • Didier Riethmuller
  • Benoit Soubeyrand
  • Pierre Van Damme
  • Xavier Bosch
Vis graf over relationer

BACKGROUND: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low risk types 6 and 11, causing genital warts.

OBJECTIVE: To estimate the lifetime risk (up to the age of 75 years) for developing cervical cancer after vaccinating a HPV naïve girl (e.g. 9 to 12 years old) with the 9vHPV vaccine in the hypothetical absence of cervical cancer screening.

METHODS: We built Monte Carlo simulation models using historical pre-screening age-specific cancer incidence data and current mortality data from Denmark, Finland, Norway, Sweden and the UK. Estimates of genotype contribution fractions and vaccine efficacy were used to estimate the residual lifetime risk after vaccination assuming lifelong protection.

RESULTS: We estimated that, in the hypothetical absence of cervical screening and assuming lifelong protection, 9vHPV vaccination reduced the lifetime cervical cancer and mortality risks 7-fold with a residual lifetime cancer risks ranging from 1/572 (UK) to 1/238 (Denmark) and mortality risks ranging from 1/1488 (UK) to 1/851 (Denmark). After decades of repetitive cervical screenings, the lifetime cervical cancer and mortality risks was reduced between 2- and 4-fold depending on the country.

CONCLUSION: Our simulations demonstrate how evidence can be generated to support decision-making by individual healthcare seekers regarding cervical cancer prevention.

OriginalsprogEngelsk
TidsskriftHuman vaccines & immunotherapeutics
Vol/bind14
Udgave nummer7
Sider (fra-til)1800-1806
Antal sider7
ISSN2164-5515
DOI
StatusUdgivet - 3 jul. 2018

ID: 56090870